Latest Tolerx Stories
-Enhances Capabilities for the Precision Medicine in Immuno-oncology and Autoimmune Disease Areas- LOS ANGELES and LEIPZIG, Germany, Sept. 17, 2014 /PRNewswire/ -- ImaginAb, Inc.
Supports progression of this first-in-class anti-TLR4 monoclonal antibody into clinical proof of concept study as a potential personalized medicine for rheumatoid arthritis GENEVA, August
MONROVIA, Calif., July 15, 2014 /PRNewswire/ -- Xencor, Inc.
Clinical program focused on reversing type 1 diabetes symptoms in patients diagnosed within six months of trial initiation EDGEWATER, N.J. and SAN DIEGO, Feb.
ROCKVILLE, Md., June 23, 2011 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that 1-year data from Protege, the Company's Phase 3 clinical study of teplizumab in type 1 diabetes patients, will be presented at the American Diabetes Association's 71st Scientific Sessions symposium in San Diego, California on June 28, 2011 at 9:10 a.m.
- Large; stout; burly.